You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
McKinsey
Baxter
McKesson
Merck
AstraZeneca

Last Updated: September 29, 2020

DrugPatentWatch Database Preview

PATADAY ONCE DAILY RELIEF Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Pataday Once Daily Relief, and when can generic versions of Pataday Once Daily Relief launch?

Pataday Once Daily Relief is a drug marketed by Novartis and is included in two NDAs. There is one patent protecting this drug.

This drug has thirty patent family members in nineteen countries.

The generic ingredient in PATADAY ONCE DAILY RELIEF is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Pataday Once Daily Relief

A generic version of PATADAY ONCE DAILY RELIEF was approved as olopatadine hydrochloride by APOTEX INC on October 8th, 2014.

  Start Trial

Summary for PATADAY ONCE DAILY RELIEF
International Patents:30
US Patents:1
Applicants:1
NDAs:2
Suppliers / Packagers: 2
Clinical Trials: 4
Formulation / Manufacturing:see details
DailyMed Link:PATADAY ONCE DAILY RELIEF at DailyMed
Drug patent expirations by year for PATADAY ONCE DAILY RELIEF
Recent Clinical Trials for PATADAY ONCE DAILY RELIEF

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AllerganPhase 4
McCabe Vision CenterN/A
Alcon ResearchPhase 4

See all PATADAY ONCE DAILY RELIEF clinical trials

Pharmacology for PATADAY ONCE DAILY RELIEF
Paragraph IV (Patent) Challenges for PATADAY ONCE DAILY RELIEF
Tradename Dosage Ingredient NDA Submissiondate
PATADAY ONCE DAILY RELIEF SOLUTION/DROPS;OPHTHALMIC olopatadine hydrochloride 206276 2015-09-10
PATADAY ONCE DAILY RELIEF SOLUTION/DROPS;OPHTHALMIC olopatadine hydrochloride 021545 2008-09-08

US Patents and Regulatory Information for PATADAY ONCE DAILY RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis PATADAY ONCE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004 OTC Yes Yes   Start Trial   Start Trial   Start Trial
Novartis PATADAY ONCE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 206276-001 Jan 30, 2015 OTC Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PATADAY ONCE DAILY RELIEF

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis PATADAY ONCE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004   Start Trial   Start Trial
Novartis PATADAY ONCE DAILY RELIEF olopatadine hydrochloride SOLUTION/DROPS;OPHTHALMIC 021545-001 Dec 22, 2004   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for PATADAY ONCE DAILY RELIEF

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0799044 02C0040 France   Start Trial PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
0799044 CA 2002 00029 Denmark   Start Trial
0799044 SPC029/2002 Ireland   Start Trial SPC029/2002: 20040930, EXPIRES: 20170516
0799044 SPC/GB02/041 United Kingdom   Start Trial SPC/GB02/041: 20021018
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
McKesson
Dow
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.